Survival and predictors of outcomes in non-HIV-infected patients with extensively drug-resistant tuberculosis

Int J Tuberc Lung Dis. 2009 May;13(5):594-600.

Abstract

Setting: A tuberculosis (TB) referral hospital in South Korea.

Objective: To evaluate predictors of treatment outcomes and survival among non-human immunodeficiency virus (HIV) infected patients with extensively drug-resistant TB (XDR-TB).

Design: Patients who were diagnosed with XDR-TB at the National Masan Tuberculosis Hospital from January 2001 to December 2005 were included in this study. We conducted a retrospective review of their medical records and mortality data.

Results: A total of 176 non-HIV-infected patients with XDR-TB were included. TB-related mortality was 48% (84/176), and the median survival time from the diagnosis date of XDR-TB was 51 months (range 0-127, 95%CI 32.53-69.47). Cure and treatment completion were classified as favourable outcome and treatment failure, death during treatment and default as poor outcome. Previous TB treatment with second-line drugs (aOR 2.76, 95%CI 1.02-7.44) and cavitary disease (aOR 3.01, 95%CI 1.12-8.08) were independent risk factors for poor outcome. Use of linezolid (aOR 0.10, 95%CI 0.01-0.69) and surgical resection (aOR 0.18, 95%CI 0.04-0.78) were associated with favourable outcome.

Conclusion: There was high mortality in non-HIV-infected patients with XDR-TB at a TB referral hospital in South Korea. Adjunctive surgical treatment and linezolid improved the outcome for selected patients with XDR-TB.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Antitubercular Agents / therapeutic use*
  • Extensively Drug-Resistant Tuberculosis / mortality*
  • Extensively Drug-Resistant Tuberculosis / therapy
  • Female
  • Follow-Up Studies
  • HIV Infections
  • Hospitals, Special / statistics & numerical data
  • Humans
  • Korea / epidemiology
  • Male
  • Pneumonectomy / methods*
  • Retrospective Studies
  • Survival Rate / trends
  • Treatment Outcome

Substances

  • Antitubercular Agents